<DOC>
	<DOC>NCT00134251</DOC>
	<brief_summary>This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease (PD) and dose-dependent motor fluctuations. Patients (outpatients) will be randomized to one of three different treatment arms.</brief_summary>
	<brief_title>Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients who have signed an informed consent; diagnosis of idiopathic PD. Presence of recognizable "on" and "off" stages Minimum hours of "off" time per day of 2.5 hours Able to keep diaries. Unclear diagnosis or a suspicion of other parkinsonian syndromes Have undergone surgical treatment for PD History of nonresponse to Ldopa.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>adjunctive to L-dopa therapy</keyword>
	<keyword>Advanced stage Parkinson's disease</keyword>
</DOC>